ASH 2021: Addition of Ivosidenib to Azacitidine Improved Outcomes in Select Patients With Untreated Acute Myeloid Leukemia
Health-related quality of life assessment also favored addition of ivosidenib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.